Cost-saving initiatives move The Star closer to achieving positive EBITDA

(AsiaGameHub) -   The Star Entertainment Group has begun to realize the benefits of its cost-reduction strategies, as its EBITDA showed a marked improvement during the third quarter compared to the same timeframe last year, despite remaining in negative territory. Among the cost-cutting steps taken by the Australian casino firm is a refinancing deal with WhiteHawk Capital Partners. This follows binding long-term agreements with Chow Tai Fook Enterprises Limited and Far East Consortium International Limited concerning the Queen’s Wharf Brisbane and Gold Coast properties. Organizational streamlining occurred at the group’s headquarters, which are now under fresh management following the finalization of a A$300m strategic investment from Bally’s Corporation and Investment Holdings late last year. In its report, The Star stated: “Additional measures, such as those targeting administrative roles at each site and prospects for lowering indirect costs and vendor outlays, are still being investigated to bolster The Star's long-term financial health and further solidify the group’s fiscal standing.” The Star sees EBITDA growth For the third quarter ending March 31, 2026, The Star posted revenue of AUS$266m (roughly €163.2m), representing a 12% decline from the second quarter ($301m) and a 1% drop year-over-year (Q3 2025: $268m). Nevertheless, EBITDA rose by 96% year-over-year to a $1m loss (compared to a $24m loss in Q3 FY25) before accounting for significant items. As of March 31, 2026, available cash was $90m. The Star attributed the Q3 performance to a "seasonal dip in revenue and lower gaming traffic in Sydney." While EBITDA improved, the operator reiterated that its "status as a going concern continues to hinge on the resolution of several significant uncertainties," many of which are linked and beyond its influence. Image: Max Stoliar/Shutterstock Performance by location: The Star Sydney: Revenue – $147m, EBITDA – $4m loss. The Star Gold Coast: Revenue – $101m, EBITDA – $8m. The Star Brisbane: Revenue – $15m, EBITDA – $4m loss. Treasury Brisbane: Revenue – $3m, EBITDA – $1m loss. Last month, the New South Wales Independent Casino Commission (NICC) once again pushed back the license suspension for The Star Sydney, with Nicolas Weeks set to continue as the facility's manager until September 30, 2026, unless his tenure is ended sooner. NICC Chief Commissioner Philip Crawford remarked at the time: “The current ownership is implementing major operational changes, which the NICC is tracking closely. “This involves efforts to ensure the business is more financially viable over the long term, helping them prove their suitability. We will persist in collaborating with The Star on their remediation goals so the casino can address the grave issues identified in the two Bell inquiries.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Cambridge study further fuels Irish gambling advertising debate

(AsiaGameHub) -   A study conducted by the University of Cambridge has intensified the discussion surrounding gambling advertisements in Ireland, coinciding with broader concerns about the gambling industry's societal effects within the nation. Ireland is currently undergoing a period of regulatory reform, with the Gambling Regulatory Authority of Ireland (GRAI) now overseeing the country’s betting market as mandated by the 2024 Gambling Regulation Act. Similar to the review of the Gambling Act in the United Kingdom, the re-regulation of Ireland's betting market has left proponents of gambling reform, such as the Labour Party, advocating for more substantial changes to advertising regulations. According to research jointly undertaken by the University of Cambridge and Munster Technological University (MTU) in Cork, gambling advertisements in Ireland disproportionately affect young men. The university's study examined social media advertising through the Meta Ad library, analyzing published advertisements and demographic data across platforms like Facebook and Instagram. Dr Elena Petrovskaya, the lead author of the report from the university’s Department of Computer Science and Technology, noted that "not that many adverts directly targeted men to begin with." However, she elaborated: "But even when adverts were set to reach all genders, they still reached that very vulnerable group of young men. “It shows that if companies just put ads on social media, they are still reaching young men – the group we know from other research is most at risk of gambling harms.” Cambridge researchers analyzed 411 advertisements from 88 licensed Irish operators, concluding that young men were 2.3 times more likely to be exposed to social media advertisements than women, despite the ads not being specifically targeted at men. Individuals in the 25-34 age group constituted one-third of all unique accounts reached, accumulating 6.2 million impressions. The researchers highlighted one particular advertisement that reached 1.32 million unique accounts. Irish advertising debate continues unabated The discourse concerning gambling in Ireland, much like in other significant European gambling markets such as the UK, Netherlands, and Italy, has largely centered on sponsorship arrangements. The presence of bookmaker branding in prominent Irish sports competitions, including the Gaelic football and hurling leagues of the Gaelic Athletic Association (GAA) and the League of Ireland (LOI), has been a contentious issue for many years. The GAA ultimately decided to cease partnerships with gambling sponsors, citing concerns regarding customer protection and societal impact. The LOI, in contrast to its English counterparts in the EFL and the governing bodies of the Premier League, has been more reluctant to sever commercial ties with the sport due to the revenue generated. The Gambling Regulation Act and the GRAI's mandate are now established, with the latter assuming licensing responsibilities this year. Nevertheless, certain political figures, such as Labour Party leader Ivana Bacik, remain firm in their conviction that a comprehensive ban on gambling advertising in Ireland is essential. Research from institutions like Cambridge and MTU is expected to play a significant role in this debate, particularly given its focus on the impact of social media advertising, adding another dimension to a discussion that has predominantly revolved around sports sponsorships and television commercials. The findings from the researchers regarding the impact of advertising on young men, who according to Irish government statistics are among those most susceptible to gambling-related harm, will be particularly important for advocates of gambling reform. “This research provides valuable insights that establish a baseline for the reach of gambling advertising on social media in Ireland before the introduction of a regulatory framework,” stated Dr Deirdre Leahy from MTU, a co-author of the research. “This baseline will be essential for assessing the impact of reforms under the Gambling Regulation Act.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

NEC Launches “Africa Corporate Innovation Program” Accelerating Business Through Co-Creation with African Startups

- In collaboration with the Shell Foundation and Double Feather Partners, NEC is promoting startups and solutions to social issues -TOKYO, Apr 28, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (TSE: 6701) has launched an initiative to strengthen collaboration with African startups and address social challenges such as agriculture and food security. The newly established "Africa Corporate Innovation Program" is in addition to NEC’s existing global startup accelerator, the "NEC Innovation Challenge", and is designed to further strengthen partnerships with startups. The program will be jointly designed and implemented by the UK-based Shell Foundation charity (Note 1) and the Double Feather Partners (Note 2, hereafter DFP) venture capital firm.NEC has been working to achieve sustainable agriculture and stronger food security in Africa by combining its advanced technological capabilities with practical insights gained from global business operations, including the provision of data-driven farming solutions.NEC has hosted the NEC Innovation Challenge since 2022 to promote co-creation with global startups. In 2024 and 2025, NEC also participated in Project NINJA (Note 3) for building startup ecosystems for innovation creation in developing countries, led by the Japan International Cooperation Agency (JICA) (Note 4), further advancing open innovation globally.Building on these initiatives, NEC began implementing the Africa Corporate Innovation Program this April in collaboration with Shell Foundation, the UK registered charity empowering underserved customers to raise their incomes while lowering emissions with funding by the UK Government via the Research on Infrastructure in Developing Economies (RIDE) program and DFP, which has strong capabilities in local co-creation design and business scaling support in Africa.Through this program, startups capable of addressing key challenges in Africa will be selected and will collaborate with NEC and partners to conduct proof-of-concept (PoC) demonstration projects that leverage the strengths of each party. Based on the outcomes of these projects, the initiative will also explore mid- to long-term business development and strategic partnerships, aiming to establish sustainable co-creation models.Program OverviewThe program leverages NEC’s ICT platform "CropScope" to build agricultural technologies, including farm to market logistics solutions, while conducting proof-of-concept (PoC) trials with African startups to establish evidence for longer-term commercial partnerships and expansion across African markets.ScheduleApril 2026:Launch of the Africa Corporate Innovation ProgramInitiate collaboration with African startupsThrough December 2026:PoC projects utilizing agricultural fields in AfricaMarch 2027:Evaluation of PoC outcomes and impact measurement, followed by a final reporting sessionMasayuki FurukawaDirector, Private Sector Development GroupJapan International Cooperation Agency (JICA)"JICA has been continuously conducting cooperation in collaboration with private-sector partners with the aim of strengthening startup ecosystems in Africa and enhancing collaboration between African and Japanese companies."This initiative holds significant value where it leverages the experience and knowledge accumulated through the Next Innovation with Japan (NINJA) project promoted by JICA, with the expectation of contributing further to Africa’s economic development. JICA supports the idea that private companies take the lead in addressing social challenges in Africa and building mutually beneficial relationships."Furthermore, JICA hopes that this initiative will encourage more Japanese companies to participate in similar efforts, thereby further expanding collaboration between startups in Japan and Africa. JICA will continue its cooperation through Project NINJA and will support promoting initiatives of this kind going forward."Jonathan BermanCEOShell Foundation"Raising incomes for people on low incomes while supporting a low carbon pathway requires more than good ideas – it requires partnerships that bring together capital, technology and local entrepreneurial expertise. Through the Africa Corporate Innovation Program, Shell Foundation is using catalytic funding to reduce the risk of collaboration and, together with our partner Double Feather Partners, help global corporates like NEC work alongside African startups to test, learn and build solutions that can scale and evolve into sustainable business partnerships. Our role is to make these partnerships possible, prove what works in practice and help unlock much larger flows of capital into inclusive, climate-smart markets."Kohei MutoRepresentative Director & CEODouble Feather Partners"Social challenges in Africa should no longer be viewed merely as development issues; they represent the frontier of one of the world’s fastest-evolving innovation markets. This program serves as an implementation platform that connects the technological strengths of Japanese companies with the field-driven innovation capabilities of African startups."DFP will design and support mechanisms that connect PoC initiatives to investment opportunities and business scale-up, maximizing NEC’s business expansion and social impact creation in Africa. In collaboration with the Shell Foundation, DFP will also support the development of sustainable business models from the perspectives of impact investment and blended finance."Through this initiative, we aim to build a new co-creation model between Japan and Africa, enabling a seamless pathway from demonstration projects to capital linkage and ultimately to business value creation."NEC is scheduled to present background on this project at the "SusHi Tech Tokyo 2026" innovation conference, held from April 27th (Monday) to 29th (Wednesday), 2026. Please see below for details.Title: Beyond Capital: Building Japan–Africa Innovation Through Co-Creation and InvestmentDate and Time: April 27th (Monday), 5:05PM-5:50PMLocation: Investor’s Stage, West 3-4 Hall 4F (Upper Floor), Tokyo Big SightParticipating Companies:Double Feather Partners, Japan International Cooperation Agency (JICA), Shell Foundation, NEC, Industrial Development Corporation of South Africa (IDC), and Absa BankFor details and registration information for SusHi Tech Tokyo 2026, please visit the official website. https://sushitech-startup.metro.tokyo.lg.jp/en/Under the key message "The future is ours to shape," NEC drives "NEC Open Innovation" (Note 5) in new business development through diverse co-creation with startups and partner companies. The Africa Corporate Innovation Program is part of that effort, and by combining cutting-edge technologies with cross-sector collaboration, NEC continues to generate new social value and shape the future.1. Shell Foundation: https://shellfoundation.org/ 2. Double Feather Partners: https://doublefeather.com/ 3. Project NINJA4. Japan International Cooperation Agency (JICA)https://www.jica.go.jp/english/index.html5. NEC Open Innovationhttps://www.nec.com/en/global/innovation/index.htmlAbout NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com.  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

The Star Reports Improved Profits Amid Bally’s Support

(AsiaGameHub) -   Australia’s leading casino brand The Star Entertainment Group has recorded a major year-on-year improvement, reporting an AU$1m (£530,000) loss for Q3 2026, down from a $24m loss in the same quarter of 2025. That said, the quarter was slightly weaker than Q2, with revenue falling and profitability slipping back into negative territory, as regulatory pressures and lower visitor numbers continued to weigh on performance. Group revenue landed at $266m, down 12% quarter-on-quarter and slightly lower than the $268m recorded in the prior corresponding period. The company posted an EBITDA loss of $1m, reversing the $6m profit it gained in Q2, though the result is still a marked improvement on 2025 figures driven by cost-cutting efforts. Declines were largely fueled by ongoing soft performance in Sydney, where revenue dropped 10% versus the previous quarter and 9% year-on-year. Table games were a particular weak point, and the impact of mandatory carded play and cash limits continues to be felt – average daily revenue at the Sydney property is still roughly 20% below pre-reform levels. Examples of these regulatory reforms include a $100 cash load-up limit for Victorian poker machines and a delayed rollout of $1,000 daily cash limits at New South Wales casinos, where the limit will remain at $5,000 until August 2027. Across other locations, performance was mixed. The Gold Coast delivered modest year-on-year growth, supported by stronger electronic gaming and hospitality results, while Brisbane’s numbers were impacted by the transition out of the Destination Brisbane Consortium (DBC) joint venture and changes to the operator fee structure. Cost reductions were a clear positive highlight, with operating expenses falling 11% quarter-on-quarter and 10% year-on-year. This reflects the early impact of “cost out” initiatives launched by the company’s new leadership team, including corporate streamlining and reviews of supplier costs. Latest updates on The Star’s turnaround plan Even so, The Star’s broader overall financial position remains fragile. Available cash dropped to $90m at the end of March, and the company is working against a tight deadline to complete refinancing by 15 May to avoid breaching its existing debt agreement. A binding refinancing commitment with WhiteHawk Capital Partners, announced at the end of last month, is already in place, and all required regulatory approvals have been secured. The refinancing package consists of a three-year facility totaling around $550m, which will be used to fully refinance the group’s existing debt while also providing extra liquidity. A minimum liquidity requirement of $50m has been set for the first 12 months after financial close, which the company is on track to meet. The requirement rises to $75m between 12 and 18 months post-close, and $100m after that period. Additional covenants include a minimum asset coverage ratio starting December 2026 and a minimum EBITDA threshold starting March 2027, alongside standard reporting obligations and default provisions. An interest reserve account that will cover the first 12 months of interest payments will also be set up as part of the new financing structure. “The Star is working to complete the refinancing as soon as possible, but no later than 15 May 2026, to meet the conditions of the waiver granted by existing SFA lenders,” a company statement read. The Star has also made progress on its strategic reset, completing the first stage of its exit from the Brisbane joint venture with DBC. This step included the release of a large parent company guarantee tied to $1.4bn in debt facilities. Financial challenges will not be resolved immediately Despite these recent steps, The Star has reiterated that material uncertainty remains over its ability to continue as a going concern, with multiple interconnected factors including refinancing, regulatory outcomes and operational recovery still unresolved. Bruce Mathieson Jnr, the company’s current Chief Executive Officer, has continued advancing the turnaround strategy, which included appointing two new Non-Executive Directors – Brooke Lindsay and Grant Bowie – this month. The business remains in a transitional period following a $300m strategic investment from Bally’s Corporation and Investment Holdings late last year, a deal that will eventually give Bally’s a 56.7% stake in The Star. The company is also navigating ongoing regulatory change across Australia, where a key recent policy focus has been cracking down on gambling advertising. The Murphy report, written by late MP Peta Murphy and holding 31 recommendations for Australian regulatory reform, has still not seen most of its suggestions implemented across the country. For The Star, an immediate return to profitability was always highly unlikely. Despite the unavoidable pressures it faces from both internal and external sources, the company is in a much healthier position today than it was at the start of 2025, when it was grappling with losses of more than $300m. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Tipico joins the Banijay era with Mate Bacic as CEO

(AsiaGameHub) -   Tipico Sportwetten has kicked off a new “leadership era”, with Mate Bacic taking over from Axel Hefer as Chief Executive Officer of the largest sports betting and iGaming brand operating in the DACH region. This leadership transition follows Hefer’s decision to resign from the new leadership team of Banijay Gaming – the division established in April 2025, after Banijay Group finalized its €3 billion acquisition of Tipico. Hefer’s exit comes after he fulfilled his remit of restructuring Tipico to position it for an eventual multi-billion-euro sale. During his three-year tenure, the company pulled out of the US market, selling its domestic US operations to MGM Resorts, and purchased Admiral Austria to boost its regional presence. The business ultimately became an acquisition target itself, when its former private equity owner CVC Capital reached an agreement to sell Tipico to Banijay in October 2025. Speaking about his departure, Hefer said: “I joined the Tipico Group nearly three years ago with one clear goal: to lay the groundwork for the company’s future international growth. Now that the sale to Banijay Group is complete, my work here has been successfully finished. “I am fully confident that with Mate Bacic leading the company and as part of Banijay Gaming, Tipico is extremely well positioned for future success. I wish Mate and the entire team all the best in the coming years.” New leadership steers the business into its next chapter Bacic, who has held executive roles at Tipico for almost a decade, has been promoted to the CEO position from the group’s existing senior leadership ranks.  As Managing Director of Tipico Retail Services, he played a key role in building and restructuring the operator’s land-based retail network, which now covers more than 1,250 outlets across Germany and Austria. Most recently, he oversaw the integration of Admiral Austria into the wider group during his tenure as CEO of the Atlas Group. Before joining Tipico, Bacic held senior leadership positions at Telefónica Germany, bringing deep operational and commercial expertise to his new top role. Discussing his new appointment, Bacic said: “I am thrilled to lead Tipico through this critical phase for the business. We have a powerful brand, a highly committed team, and trusted partners supporting us. Working alongside Banijay, we will speed up innovation efforts, invest in technology, and set new benchmarks for customer service.” He added: “We aim to deliver the best and most secure experience possible for sports betting fans — both online and across our more than 1,250 retail shops. I also want to thank Axel for his reliable partnership and his significant contributions to putting Tipico in such a strong position for the future.” Credit: Tobias Arhelger / Shutterstock Under the revised leadership structure, Nicolas Béraud, former Betclic CEO, will serve as Chairman of the Board of Banijay Gaming. Joachim Baca, Chairman and former CEO of Tipico, will act as Vice-Chairman of the Board. Operational leadership roles across the group’s core brand portfolio have also been reshuffled, with Julien Brun, previously Chief Operational Officer, stepping into the role of CEO of Betclic. Banijay’s leadership team has given its full endorsement to this internal succession, with Béraud stating: “Following the completion of Banijay Gaming’s acquisition of the Tipico Group, I am convinced that Mate, with his extensive industry experience, in-depth understanding of the Tipico Group, and strong leadership capabilities, will make a major contribution to building our large-scale European gaming platform. “Axel was an exceptional partner throughout the Betclic/Tipico transaction, and I wish him all the best for the next chapter of his career.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

迈威生物登陆港交所 早盘高开2.39% 核心ADC管线步入收获期

香港, 2026年4月28日 - (亚太商讯 via SeaPRwire.com) - 4月28日,迈威(上海)生物科技股份有限公司(02493.HK,简称“迈威生物”)成功在香港联合交易所主板挂牌上市,成为又一家“A+H”两地上市的生物科技公司,亦是首家AtoH的18A公司。迈威生物本次全球发售4713.02万股H股,香港公开发售部分超额认购481.71倍,市场反响热烈。强劲的认购态势不仅为发行提供了稳固支撑,也折射出市场对于迈威研发管线与商业化前景的集体看好。迈威生物是一家具备创新研发及端到端产业化能力的中国制药公司。其核心产品9MW2821(靶向Nectin-4)在中国尿路上皮癌临床开发进度仅次于Padcev,且为全球首款进入宫颈癌关键III期试验的同靶点ADC。该产品已获得FDA三项快速通道认定及一项孤儿药资格认定,并获国家药监局两项突破性疗法认定。公司正同步推进该产品针对多项适应症的III期临床试验,计划于2027年提交尿路上皮癌和宫颈癌的NDA申请。若进展顺利,9MW2821有望成为中国首款覆盖多个实体瘤适应症的Nectin-4 ADC,潜在市场空间巨大。迈威生物已有君迈康(R)、迈利舒(R)、迈卫健(R)及迈粒生(R)四款产品实现商业化。2025年公司总收入达6.59亿元人民币,同比增长230%。对外授权合同总金额超过20亿美元,贡献显著。公司与Disc、Calico等国际药企达成的许可协议已带来可观的首付款和里程碑付款,充分验证了其技术成果的国际化变现能力。公司的生产端亦具备国际标准。江苏泰州生产基地符合中国GMP标准及欧盟EMA GMP标准,上海金山生产基地亦符合欧盟EMA GMP标准,为后续产品放量提供保障。迈威生物凭借其差异化的ADC管线及已兑现的商业化能力,加速推进核心产品的上市进程,在全球肿瘤及年龄相关疾病领域持续巩固其竞争优势。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

旭阳集团与杭氧集团签署战略合作协议 共筑氢能全产业链新生态

香港, 2026年4月28日 - (亚太商讯 via SeaPRwire.com) - 2026年4月24日,旭阳集团有限公司(简称"旭阳集团")与杭氧集团股份有限公司(简称"杭氧集团")在杭州正式签署战略合作协议。双方将立足京津冀雄和长三角区域,面向全国,在氢能供应体系、高端装备国产化、技术创新及产业投资等领域开展全方位、深层次合作,共同推动我国氢能产业高质量发展。旭阳集团在工业副产氢领域拥有超过30年深厚积累,是全球最大的独立焦炭生产商及供应商;全球最大焦化粗苯加工商、第二大高温煤焦油加工商和己内酰胺生产商(按产能计),亦是中国最大的焦炉煤气制甲醇生产商和京津冀最大的高纯氢供应商(按产量计),中国旭阳集团(1907.HK)2019年3月成功在香港联交所主板上市,已形成覆盖"制-储-运-加-用+研"的完整氢能产业链。杭氧集团股份有限公司(002430.SZ)2010年在深圳证券交易所上市,是世界一流的空分设备和低温石化装备供应商,中国气体的产业开拓者和引领者,亦是国内第一台空分设备制造者;其大型、特大型空分设备产量和销量全球第一,总体技术达到国际领先水平,在气体运营及氢能技术研发方面具备领先优势。此次合作是双方优势资源的战略级整合,将旭阳氢源基础与应用场景,与杭氧的装备技术及气体产业能力深度融合,为氢能全产业链生态建设注入强劲动力。聚焦三大合作方向,释放协同发展新动能本次合作将重点围绕氢能销售与供应体系的共建、高端装备国产化应用,以及技术创新与产业化落地展开。双方将通过业务对接与资源协同,构建"液氢生产基地+区域储氢枢纽+加氢站网络"三级供应体系,共同拓展工业、交通、电子、医药、航天等终端市场。同时,双方将联合推进氢能领域关键装备与系统的国产化进程,并在旭阳定州氢能生产基地共建氢能装备测试与技术创新中心,聚焦液氢及加氢站核心部件的验证与攻关,携手申报国家级科研项目及行业标准。为进一步深化合作,双方还拟共同出资设立合资公司,主营氢气/液氢销售、氢能装备制造及技术服务,加速科技成果的产业化落地。合作前景:从资源优势迈向全链引领此次战略合作,标志着旭阳集团氢能产业正加速从"资源优势"向"全链优势"跃升。通过与杭氧集团的强强联合,旭阳将有效补齐在高端装备和气体运营网络方面的关键环节,显著提升氢能产品的市场覆盖能力与流通效率,并借助国产化装备的规模化应用,降低全链条成本,增强核心竞争力。对于杭氧集团而言,合作将助其从传统空分及低温装备领域,深度切入工业副产氢这一丰富的氢能源头,拓展液氢及高纯氢的应用场景,抢占氢能装备与气体服务的市场先机。面向未来,双方将以此次合作为起点,构建可复制、可推广的氢能产业生态。未来合资公司的设立更将为双方带来长期稳定的业务增长极,推动旭阳集团从焦化龙头向全球领先的清洁能源解决方案提供商加速转型,同时也助力杭氧集团实现从装备制造向"装备+服务+运营"的产业链延伸。在国家"双碳"目标的引领下,旭阳与杭氧的携手,将为我国氢能产业的高端化、规模化和国际化发展树立新的标杆。杭氧集团党委副书记童俊表示:"旭阳集团在工业副产氢及氢能应用场景方面具有独特优势。杭氧将全力支持双方深度合作,共同推动我国氢能产业迈向高端化、规模化、国际化。"旭阳集团高级副总裁张英伟表示:"杭氧集团在低温装备和气体运营方面拥有世界级的技术实力。本次合作是旭阳氢能产业的关键跃升,我们将充分发挥互补优势,加快打造氢能产业生态,助力国家‘双碳’目标实现。"关于战略合作协议,双方已建立高层沟通机制和联合工作小组,确保合作高效落地。未来,旭阳集团将继续秉持开放、协同、共赢的理念,携手产业链优秀伙伴,为构建清洁低碳、安全高效的现代能源体系贡献旭阳力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical industry is ushering in a golden cycle of development. As a representative enterprise in China's innovative pharmaceutical sector, Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell” or the “Company”, stock code: 02493.HK) has seized industry development opportunities by leveraging its profound R&D foundation, integrated whole-industry-chain advantages, and forward-looking global layout. Today, it officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX), joining the biopharmaceutical sector of the Hong Kong stock market and opening a brand-new chapter in its international development.Reportedly, founded in 2017, Mabwell is a leading domestic innovative pharmaceutical enterprise, possessing premier innovative drug R&D capabilities and end-to-end whole-industry-chain capabilities that span from drug discovery to commercial sales. Since its establishment, the Company has been deeply engaged in therapeutic areas for major diseases such as oncology, immunology, ophthalmology, and orthopedics, and is committed to providing safer and more efficient innovative treatment solutions for patients worldwide.Rich and Diversified Product Pipeline Builds Core Competitive BarriersA rich and promising product portfolio serves as the core pillar for Mabwell’s steady development, as well as its key advantage in seizing first-mover opportunities in the market. With a long-term, deep-rooted presence in the innovative drug sector, the Company has built a diversified product pipeline featuring multiple categories and tiers. As of now, Mabwell has 4 commercialized products and 10 drug candidates: 1 in NDA stage,, 1 in preclinical stages, covering multiple high-potential therapeutic areas and supporting long-term growth.Mabwell’s self-developed core product, 9MW2821, fully demonstrates the Company’s leading edge in the ADC field. 9MW2821 is the most advanced among all Nectin-4-targeting ADCs for urothelial carcinoma (“UC”) in China in terms of clinical development progress, and only second to the globally blockbuster drug Padcev. Meanwhile, it is also the first Nectin-4-targeting ADC globally to enter the pivotal Phase III clinical trials for cervical cancer (“CC”), and triple-negative breast cancer (“TNBC”), boasting extensive market potential.Beyond 9MW2821, Mabwell continues to advance the R&D of ADC candidates targeting other novel targets and has built a comprehensive ADC pipeline portfolio. Its pipeline includes 7MW3711, an ADC specifically targeting B7-H3 (an immune checkpoint protein), and 7MW4911, an ADC specifically targeting CDH17. This layout further diversifies the Company’s footprint in oncology treatment and steadily consolidates its leading advantages in the ADC track.Notably, Mabwell has also strategically prioritized the layout of product pipelines covering monoclonal antibodies (“mAbs”), TCE bispecific antibodies, fusion proteins and small molecule drugs, fostering a pattern of coordinated development across multiple product categories. Its R&D portfolio includes: 9MW3811, a humanized monoclonal antibody targeting IL-11 for the treatment of fibrosis -related diseases and cancers; 9MW1911, the first domestically developed drug candidate approved for clinical development in China targeting ST2; 9MW3011, a recombinant humanized TMPRSS6 targeting mAb among the leading TMPRSS6-targeting therapies in terms of development status globally; and 6MW5311, the world’s first LILRB4/CD3-targeted TCE bispecific antibody filed for clinical trials. These candidates keep expanding the boundaries of the Company’s innovative drug research and development.Outstanding commercialization capabilities, expanding a global market footprintLeveraging its fully integrated industry chain capabilities and forward-looking commercialization strategy, Mabwell (Shanghai) Bioscience Co., Ltd. has continued to deliver tangible commercialization outcomes. In 2025, the Company’s Junmaikang® obtained marketing approval in Indonesia, while Mailisheng® and Maiweijian were approved for commercialization in Pakistan, marking steady progress in its international commercialization efforts.Since 2022, the Company has actively expanded overseas collaborations, entering into multiple landmark international partnership agreements and securing corresponding revenue-sharing arrangements. It has successfully penetrated emerging markets including Brazil, Indonesia, Saudi Arabia, and countries along the Belt and Road Initiative, establishing an extensive global commercial network.In terms of global partnerships, Mabwell has further deepened its international presence. In January 2023, the Company entered into an exclusive licensing agreement with Disc Medicine for 9MW3011, under which it is entitled to receive up to US$412.5 million in upfront payments, milestone payments, and royalties. In June 2025, it reached an exclusive licensing agreement with Calico Life Sciences for 9MW3811, with total potential consideration exceeding US$600 million, including upfront, milestone, and royalty payments. In October 2025, the Company signed an exclusive licensing agreement with Kalexo Bio for a novel dual-target siRNA candidate drug, further expanding the breadth and depth of its international market collaborations.Powerful Technology Platforms Lay a Solid Foundation for Innovation-Driven GrowthPowerful technology platforms serve as the core engine for sustained innovation at Mabwell, and are also pivotal to building differentiated competitive advantages. With deep commitment to technological R&D, the Company has established four core ADC technologies for which we possess proprietary intellectual property rights, providing strong support for the development of innovative drugs.Among these, DARfinity is a self-developed site-specific conjugation process that enables precise drug molecule conjugation; IDconnect is an optimized design of linker molecules that enhances the stability of the linkage between the antibody and toxins; Mtoxin is a class of camptothecin-based novel toxic molecules that are used as the “warhead” in the ADC to kill the targeted cells, providing more potent target cell killing effects; LysOnly is an innovative structure that allows conditional release of toxins, effectively improving the overall safety and efficacy of ADC drugs.These four proprietary technologies serve as the core pillars of our site-specific conjugation ADC development platform, synergistically enabling the Company to develop ADC products with better uniformity, stability, purity, and a superior efficacy and safety profile. This significantly improves pipeline R&D efficiency, allows rapid response to clinical and market demands, and continuously consolidates the Company's leading position in the ADC field.In addition, Mabwell continues to develop and upgrade other core technology platforms, forming a multi-technology synergistic development system. These platforms include the integrated high-efficiency antibody discovery platform and the T-cell engager (TCE)-based bi/tri-specific antibody development platform, among others. The TCE-based bi/tri-specific antibodies developed on these platforms can simultaneously and specifically bind to tumor-associated antigens and the T-cell CD3 epitope, thereby laying a solid technical foundation for the Company's strategic positioning in the field of immunotherapy.From an industry perspective, the global biopharmaceutical sector, as a core segment, has continued to gain momentum in recent years. The global oncology drug market grew from US$143.5 billion in 2019 to US$253.3 billion in 2024 with a CAGR of 12.0%, and is expected to further increase to US$375.9 billion, and US$548.2 billion in 2028, and 2032 respectively, with CAGRs of 10.4% from 2024 to 2028 and 9.9% from 2028 to 2032, respectively. This trend presents substantial growth opportunities for leading industry players like Mabwell, which possess core technologies and a globalized footprint.Driven by in-house R&D, supported by integrated end-to-end capabilities across the entire industry chain, and guided by a long-term global strategy, Mabwell continues to advance steadily in the innovative pharmaceutical sector. Leveraging a robust product pipeline, strong technological expertise, and well-established commercialization capabilities, the Company has built a solid competitive position. Its successful listing in Hong Kong will further accelerate the development of its core products, enhance its commercialization strategy, and strengthen its core competitiveness. This, in turn, is expected to position the Company at the forefront of the biopharmaceutical wave, with strong long-term growth potential that merits close market attention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

51WORLD Grants 940,200 RSUs for the First Time via Share Repurchase

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Beijing 51WORLD Digital Twin Technology Co., Ltd. (“the Company”, Stock Code: 6651.HK) announced on 27 April 2026 the first grant of 940,200 restricted share units (RSUs) to 303 employees under its 10-year RSU Scheme, representing approximately 0.23% of the Company’s total issued shares.The underlying shares will be sourced from existing H Shares acquired by the Trust on the secondary market and/or treasury H Shares repurchased by the Company using its own funds. Vesting of the award shares shall be 25% after 12 months from acceptance, and the remaining 75% shall vest in 12 quarterly instalments at 6.25% each until fully vested.The RSU Scheme is intended to align the interests of the core team with the long-term development of the Company and enhance the incentive mechanism for talent attraction and retention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com